Clinical trial NCT01195311: A Dose-escalation Study in Subjects With Advanced Malignancies
Official title: A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumors and Hematologic Malignancy
Keywords: Refractory, Advanced malignancies
Lead sponsor: Incyte Corporation
Sponsor class: INDUSTRY
First posted: 2010-09-06
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open label, dose escalation study using a 3 + 3 design to determine if INCB024360 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies. Patients will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group is enrolled and may begin to receive study drug. For subject safety, the first subject in each cohort will be administered drug for one week before the next two subjects in the cohort can begin drug administration. Doses will be escalated unless a dose-limiting toxicity (DLT) is observed in one of three subjects.

An expanded cohort of up to 15 patients may be recruited to further explore safety at the 'maximum tolerated dose' or at a lower, pharmacologically active, dose.


Eligibility criteria: Inclusion Criteria:

* Subjects with neoplastic disease refractory to currently available therapies or for which no effective treatment is available
* Subjects with life expectancy of 12 weeks or longer.
* Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

Exclusion Criteria:

* Subjects who received any anti-cancer medications in the 21 days prior to receiving their first dose of study medication or 6 weeks for mitomycin-C or nitrosoureas.
* Subjects with history of brain metastases or spinal cord compression.
* Subjects who have undergone a bone marrow or solid organ transplant.
* Subjects who have had major surgery within 4 weeks prior to study entry or had minor surgical procedure within 7 days prior to initiating treatment.
* Subjects with a history of any gastrointestinal condition
* Is receiving any compound that is known to be a potent inducer or inhibitor of CYP3A4
* Subjects with an active autoimmune process or is receiving therapy for an autoimmune disease
* Subjects treated with a serotonin reuptake inhibitor within 3 weeks prior to study entry

Primary outcomes:
measure: Safety and tolerability as measured by adverse events and dose limiting toxicities
timeFrame: Measured from baseline through follow-up period (measured during cycle 1 weekly and bi monthly thereafter)
Secondary outcomes:
measure: Tumor assessment as measured by RECIST criteria
timeFrame: Measured from baseline through treatment cessation. (Measured every other cycle and end of study)
measure: Measurement of IDO inhibition in whole blood measured through blood sampling.
timeFrame: Cycle 1, Day 1 and each 28 day subsequent cycle at Day 1
measure: PK analysis
timeFrame: Full PK at Days 1, 8 (trough only), 15 at Cycle 1 and trough at each subsequent cycle at Day 1
Other outcomes:
Locations:
city: Chicago
country: United States
state: Illinois
city: Philadelphia
country: United States
state: Pennsylvania
Study officials:
affiliation: Incyte Corporation
name: Lance Leopold, MD
role: STUDY_DIRECTOR
References: